The Novavax vaccine achieved an overall efficacy of 90.4% and provides 100% protection against moderate to severe disease in phase III clinical trials conducted in the United States and Mexico, according to the US biotechnology company today.
“Today, Novavax is one step closer to addressing the critical and ongoing global public health need for additional vaccines for COVID-19,” said the aforementioned company’s president and CEO, Stanley C. Erk, in a statement.
These clinical results reinforce that NVX-CoV2373 is highly effective and provides complete protection against moderate to severe COVID-19 infection. Novavax continues to work with a sense of urgency to complete our regulatory filings and deliver this vaccine, based on good knowledge and a proven platform, to a world still in dire need of vaccines.”
The study was launched in December and enrolled 29,960 adults at 113 sites in the United States and six in Mexico, with some participants given a placebo and others two doses of Novavax 21 days apart.
The company said the vaccine is “generally well tolerated” and common side effects include injection site pain, lasting less than three days, and fatigue, headache and muscle aches, lasting less than two days.
“PREVENT-19 confirms that NVX-CoV2373 delivers a reassuring picture of safety and tolerability,” Gregory M. Glenn, Head of Research and Development, said in a press release.
These data demonstrate consistent and high levels of efficacy and reaffirm the vaccine’s ability to prevent COVID-19 amid the ongoing genetic evolution of the virus. Our vaccine will be an important part of the COVID-19 solution and we are grateful to the study participants and trial staff who made this study possible, as well as our supporters, including the US government.”
According to Novavax, there were 77 cases of Covid-19 infection that appeared among the participants during the study, 63 cases in the placebo group and 14 cases in the vaccine group, and the company indicated that all cases in the vaccine group were mild while. There were ten moderate cases and four severe cases in the placebo group, indicating 100% efficacy of the vaccine against moderate or severe disease.
It also reported that most cases occurred in people considered “high-risk”, over 65 years of age, with some comorbidities or with repeated exposure to Covid-19, while declaring that the effectiveness of the vaccine was 91% at “high risk”. “The population.
The final analysis of results from the UK’s Phase III trial of Novavax, which was announced in March, showed that the vaccine had an overall efficacy of 89.7%, and an efficacy of 96.4% against the coronavirus strain. original and 86.3% against variant B. 1.1.7. It was first identified in the UK.
Read also: Millions of doses of J&J vaccine will be discarded after technical error
You may also be interested in:
• All sports in: La Deportiva
• Listen to the notes The most important in: LT20 Radio Junin
• Listen to Radio Junin LT20 in vivo: listen now